<DOC>
	<DOCNO>NCT02147951</DOCNO>
	<brief_summary>Expanded access Talimogene Laherparepvec subject unresected , stage IIIb IVM1c Melanoma .</brief_summary>
	<brief_title>Expanded Access Protocol Talimogene Laherparepvec Subjects With Unresected , Stage lllB IVM1c Melanoma</brief_title>
	<detailed_description>Expanded access Talimogene Laherparepvec subject unresected , stage IIIb IVM1c Melanoma may meet eligibility criterion enroll another ongoing Talimogene Laherparepvec study access enroll ongoing Talimogene Laherparepvec study .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<criteria>Histologically confirm diagnosis melanoma Subject unresected stage lllB IVM1c melanoma regardless prior therapy Subject eligible access ongoing talimogene laherparepvec clinical trial Candidate intralesional therapy ( ie , disease appropriate direct injection use ultrasound guidance ) define one following : subject previously treat talimogene laherparepvec : least 1 injectable cutaneous , subcutaneous , nodal melanoma lesion ≥ 10 mm long diameter , multiple injectable melanoma lesion aggregate long diameter ≥ 10 mm subject previously treat talimogene laherparepvec : least 1 injectable cutaneous , subcutaneous , nodal melanoma lesion must present ( minimal size criterion ) Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 , 2 Adequate organ function determine within 35 day prior enrollment Serum LDH level less equal 1.5 ULN within 35 day prior enrollment For subject previously receive talimogene laherparepvec another clinical trial , subject must end treatment reason ( ) disease progression intolerability talimogene laherparepvec Clinically active cerebral metastasis . Subjects 3 ( neurological performance status 0 ) cerebral metastasis may enrol , provide lesion adequately treat stereotactic radiation therapy , craniotomy , gammaknife therapy , evidence progression , required steroid , least two ( 2 ) month prior enrollment . Greater 3 visceral metastasis ( include lung metastasis nodal metastasis associated visceral organ ) . For subject le equal 3 visceral metastasis , lesion &gt; 3 cm , liver lesion must meet RECIST criterion stable disease least 1 month prior enrollment . Bone metastases Primary ocular mucosal melanoma History evidence symptomatic autoimmune pneumonitis , glomerulonephritis , vasculitis , symptomatic autoimmune disease Evidence clinically significant immunosuppression Active herpetic skin lesion prior complication HSV1 infection ( eg , herpetic keratitis encephalitis ) Requires intermittent chronic systemic ( intravenous oral ) treatment antiherpetic drug ( eg , acyclovir ) , intermittent topical use Currently receive treatment another investigational device drug study besides talimogene laherparepvec , less 28 day since end treatment another investigational device drug study ( ) Other investigational procedure participate protocol exclude Known acute chronic active hepatitis B hepatitis C infection Known human immunodeficiency virus infection History malignancy within past 3 year follow exception : malignancy treat curative intent know active disease present ≥ 3 year enrollment felt low risk recurrence treat physician adequately treated nonmelanoma skin cancer lentigo maligna without evidence disease adequately treat cervical carcinoma situ without evidence disease adequately treat breast ductal carcinoma situ without evidence disease prostatic intraepithelial neoplasia without evidence prostate cancer adequately treat urothelial papillary noninvasive carcinoma carcinoma situ Subject know sensitivity product component administer dose History evidence clinically significant disorder , condition disease ( exception outline ) , opinion investigator Amgen medical monitor , consult , would pose risk subject safety interfere protocol evaluation , procedures completion Female subject pregnant breastfeeding , plan become pregnant protocol treatment 3 month last dose talimogene laherparepvec Female subject childbearing potential unwilling use acceptable method ( ) effective contraception protocol treatment 3 month last dose talimogene laherparepvec</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>95 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Melanoma</keyword>
</DOC>